Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Hutrukin in Healthy Subjects
NCT05098080Phase 1Completed
- Sponsor
- XBiotech Inc.
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Hutrukin in ischemic stroke (4 arms), sponsored by XBiotech Inc. Primary endpoint: Treatment Related Adverse Events at 28 days. Started Apr 2023; status: completed.
02
Drugs
Hutrukin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05098080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098080.